| Alopecia areata and health‐related quality of life: a systematic review and meta‐analysis F Rencz, L Gulácsi, M Péntek, N Wikonkál, P Baji, V Brodszky British journal of dermatology 175 (3), 561-571, 2016 | 238 | 2016 |
| EQ-5D in central and Eastern Europe: 2000–2015 F Rencz, L Gulácsi, M Drummond, D Golicki, V Prevolnik Rupel, J Simon, ... Quality of Life Research 25, 2693-2710, 2016 | 146 | 2016 |
| Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria L Gulácsi, AM Rotar, M Niewada, O Löblová, F Rencz, G Petrova, I Boncz, ... The European journal of health economics 15, 13-25, 2014 | 119 | 2014 |
| Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary E Herédi, F Rencz, O Balogh, L Gulácsi, K Herszényi, P Holló, H Jókai, ... The European Journal of Health Economics 15, 111-119, 2014 | 101 | 2014 |
| A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia V Brodszky, F Rencz, M Péntek, P Baji, PL Lakatos, L Gulácsi Expert review of pharmacoeconomics & outcomes research 16 (1), 119-125, 2016 | 94 | 2016 |
| Parallel valuation of the EQ-5D-3L and EQ-5D-5L by time trade-off in Hungary F Rencz, V Brodszky, L Gulácsi, D Golicki, G Ruzsa, AS Pickard, EH Law, ... Value in Health 23 (9), 1235-1245, 2020 | 85 | 2020 |
| The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries L Gulácsi, V Brodszky, P Baji, F Rencz, M Péntek Advances in Therapy 34, 1128-1144, 2017 | 82 | 2017 |
| Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe F Rencz, M Péntek, M Bortlik, E Zagorowicz, T Hlavaty, A ¦liwczyński, ... World Journal of Gastroenterology: WJG 21 (6), 1728, 2015 | 82 | 2015 |
| Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey M Moradi, F Rencz, V Brodszky, A Moradi, O Balogh, L Gulácsi Archives of Iranian medicine 18 (3), 0-0, 2015 | 70 | 2015 |
| Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients AK Poór, F Rencz, V Brodszky, L Gulácsi, Z Beretzky, B Hidvégi, P Holló, ... Quality of Life Research 26, 3409-3419, 2017 | 69 | 2017 |
| A detailed analysis of ‘not relevant’responses on the DLQI in psoriasis: potential biases in treatment decisions F Rencz, AK Poór, M Péntek, P Holló, S Kárpáti, L Gulácsi, A Szegedi, ... Journal of the European Academy of Dermatology and Venereology 32 (5), 783-790, 2018 | 68 | 2018 |
| Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis F Rencz, L Gulácsi, M Péntek, AK Poór, M Sárdy, P Holló, A Szegedi, ... British Journal of Dermatology 179 (5), 1102-1108, 2018 | 65 | 2018 |
| Psychometric properties of the Hungarian version of the eHealth Literacy Scale Z Zrubka, O Hajdu, F Rencz, P Baji, L Gulácsi, M Péntek The European Journal of Health Economics 20, 57-69, 2019 | 63 | 2019 |
| Use of biologics for psoriasis in Central and Eastern European countries F Rencz, L Kemény, JZ Gajdácsi, W Owczarek, P Arenberger, GS Tiplica, ... Journal of the European Academy of Dermatology and Venereology 29 (11), 2222 …, 2015 | 63 | 2015 |
| Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease F Rencz, PL Lakatos, L Gulácsi, V Brodszky, Z Kürti, S Lovas, J Banai, ... Quality of Life Research 28, 141-152, 2019 | 53 | 2019 |
| Is the DLQI appropriate for medical decision-making in psoriasis patients? AK Poór, V Brodszky, M Péntek, L Gulácsi, G Ruzsa, B Hidvégi, P Holló, ... Archives of Dermatological Research 310, 47-55, 2018 | 49 | 2018 |
| Access to biologicals in Crohn’s disease in ten European countries M Péntek, PL Lakatos, T Oorsprong, L Gulácsi, M Pavlova, W Groot, ... World journal of gastroenterology 23 (34), 6294, 2017 | 49 | 2017 |
| Validity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in Hungary F Rencz, B Tamási, V Brodszky, L Gulácsi, M Weszl, M Péntek The European Journal of Health Economics 20, 43-55, 2019 | 48 | 2019 |
| Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods F Rencz, M Péntek, PFM Stalmeier, V Brodszky, G Ruzsa, E Gradvohl, ... Pain 158 (11), 2259-2267, 2017 | 47 | 2017 |
| Biosimilars for the management of inflammatory bowel diseases: economic considerations L Gulacsi, M Pentek, F Rencz, V Brodszky, P Baji, Z Vegh, KB Gecse, ... Current medicinal chemistry 26 (2), 259-269, 2019 | 45 | 2019 |
